Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of Zoliflodacin in Healthy Subjects
NCT03718806Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zoliflodacin in gonorrhea (2 cohorts), sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Maximum Plasma Concentration (Cmax) at Day 3, Time to Maximum Plasma Concentration (Tmax) at Day 3 and 2 more. Started Oct 2018; status: completed.
02
Drugs
zoliflodacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT03718806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718806.